<DOC>
	<DOCNO>NCT00947154</DOCNO>
	<brief_summary>No medication reliably show benefit suffer trichotillomania ( compulsive hair pull ) . The current study proposes evaluate effectiveness medication aripiprazole treatment trichotillomania ( TTM ) . Patients take gradually increase dose medication open-label study see whether relief hair-pulling urge , decrease hair pull behavior well tolerate .</brief_summary>
	<brief_title>Trial Aripiprazole Trichotillomania</brief_title>
	<detailed_description>The propose study 8-week , open-label trial aripiprazole . The study would enroll 10 patient diagnose TTM meet DSM-IV criterion . Subjects would start dose 5 mg , reduce 2 mg initial dose tolerate . Dose increase 5 mg every two week ( tolerate , minimum increase 2 mg ) maximum target dose 15 mg reach begin week 5 . Dosing would increase patient show clinical improvement low dose ( defined 30 % reduction Massachusetts General Hairpulling Scale ) intolerant dose increase . Dose may increase week 5 ; point may decrease intolerability . Modified dose aripiprazole automatically happen patient take fluoxetine paroxetine , awareness increase aripiprazole level associate P450 2D inhibition ( consequent tolerability give dose ) may factor clinical decision increase , maintain decrease aripiprazole dosage . Effectiveness : The primary measure drug effect would change baseline endpoint Massachusetts General Hospital Hairpulling Scale ( MGHHS ) well actual-pulling subscale ( item 4,5,6 ; MGHHS-AP ) . Secondary measure would include Clinical Global Impressions_Improvement scale ( CGI-I ) , 17-item Hamilton Depression Scale ( HAM-D ) Hamilton Anxiety Scale ( HAM-A ) . Assessments : Primary efficacy measure assess baseline end week 2 , 4 , 6 8 , early termination . Week 2 6 follow-up may occur telephone . Safety tolerability assess two-week interval . Secondary end-points assess baseline week 4 8 , early termination . Type Number Experimental Subjects Controls : This study would enroll 10 patient Stanford single-site study . Inclusion exclusion criterion describe separately . Children include propose study , Investigator clinical competency child psychiatry childhood Trichotillomania may different disorder condition see adult .</detailed_description>
	<mesh_term>Trichotillomania</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Eligible patient : Must outpatient age 18 65 start study May male female Have DSMIV trichotillomania least 6 month duration Allowed psychotropic medication limit : SSRIs ( citalopram , escitalopram , fluoxetine , fluvoxamine , paroxetine , sertraline ) , SNRIs ( duloxetine , venlafaxine ) mirtazapine , long dosage change 4 week prior study enrollment . Other allowed medication include nonhypnotic sleeping agent , specifically trazodone , diphenhydramine , hydoxyzine ramelteon . If patient take nonallowed psychotropic medication , he/she must titrate prescribe physician medication least 2 week prior trial enrollment . We exclude patient meet DSMIV criterion : body dysmorphic disorder ; major depression ; dysthymia ; GAD , social phobia , panic disorder . We exclude patient suffer : organic mental disorder ; psychotic mental disorder include delusional disorder , somatic type ; mental retardation developmental disability ; substance alcohol abuse ; depressive disorder current suicidal risk ; factitious disorder ; dissociative disorder ; obsessive compulsive disorder ; personality disorder sufficiently severe interfere cooperation study ; bipolar I II disorder . Patients take psychotropic agent specifically listed item . If patient take nonallowed psychotropic medication , he/she must titrate medication prescribe physician medication 2 week prior trial enrollment . Pregnant nursing woman . Patients know hypersensitivity allergy aripiprazole .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>trichotillomania</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>treatment</keyword>
</DOC>